Special AT-rich Sequence Binding-Protein 1 (SATB1) Correlates with Immune Infiltration in Breast, Head and Neck, and Prostate Cancer

Hua Ge; Yan Yan; Maozhao Yan; Lingfei Guo; Kun Mao

doi:10.12659/MSM.923208

20 June 2020: Database Analysis

Special AT-rich Sequence Binding-Protein 1 (SATB1) Correlates with Immune Infiltration in Breast, Head and Neck, and Prostate Cancer

Hua Ge ^1ABCDEF* , Yan Yan ^2BCDE , Maozhao Yan ^1CEF , Lingfei Guo ^1EF , Kun Mao ^1CF

DOI: 10.12659/MSM.923208

Med Sci Monit 2020; 26:e923208

Authors information Article notes Copyright and License information

View HTML version

Table 1 Relation between SATB1 expression and patient prognosis in different cancer using PrognosScan database.

Cancer type	Dataset	Endpoint	Array type	N	Cox P-value	HR [95% CI]
Bladde cancer	GSE5287	Overall survival	HG-U133A	30	0.057	0.55 [0.30–1.02]
	GSE13507	Overall survival	Human-6 v2	165	0.151	0.77 [0.54–1.10]
	GSE13507	Disease specific survival	Human-6 v2	165	0.018	0.53 [0.32–0.90]
Blood cancer	GSE12417-GPL96	Overall survival	HG-U133A	163	0.299	1.20 [0.85–1.68]
	GSE12417-GPL570	Overall survival	HG-U133_Plus_2	79	0.709	0.90 [0.51–1.57]
	GSE5122	Overall survival	HG-U133A	58	0.763	0.93 [0.56–1.53]
	GSE8970	Overall survival	HG-U133A	34	0.788	0.93 [0.55–1.57]
	GSE4475	Overall survival	HG-U133A	158	0.924	0.98 [0.71–1.36]
	E-TABM-346	Event free survival	HG-U133A	53	0.388	0.81 [0.50–1.31]
	E-TABM-346	Overall survival	HG-U133A	53	0.238	0.75 [0.46–1.21]
	GSE16131-GPL96	Overall survival	HG-U133A	180	0.116	0.76 [0.54–1.07]
	GSE2658	Disease specific survival	HG-U133_Plus_2	559	0.384	0.92 [0.76–1.11]
Brain cancer	GSE4271-GPL96	Overall survival	HG-U133A	77	0.004	0.60 [0.43–0.85]
	GSE7696	Overall survival	HG-U133_Plus_2	70	0.759	0.95 [0.70–1.30]
	MGH-glioma	Overall survival	HG-U95A	50	0.038	0.70 [0.50–0.98]
	GSE4412-GPL96	Overall survival	HG-U133A	74	0.101	0.69 [0.44–1.08]
	GSE16581	Overall survival	HG-U133_Plus_2	67	0.342	1.86 [0.52–6.66]
Breast cancer	GSE19615	Distant metastasis free survival	HG-U133_Plus_2	115	0.311	0.62 [0.25–1.56]
	GSE3143	Overall survival	HG-U95A	158	0.405	1.19 [0.79–1.78]
	GSE7849	Disease free survival	HG-U95A	76	0.857	1.05 [0.59–1.88]
	GSE12276	Relapse free survival	HG-U133_Plus_2	204	0.604	0.95 [0.80–1.14]
	GSE6532-GPL570	Distant metastasis free survival	HG-U133_Plus_2	87	0.463	0.86 [0.58–1.28]
	GSE6532-GPL570	Relapse free survival	HG-U133_Plus_2	87	0.463	0.86 [0.58–1.28]
	GSE9195	Distant metastasis free survival	HG-U133_Plus_2	77	0.178	1.57 [0.82–3.01]
	GSE9195	Relapse free survival	HG-U133_Plus_2	77	0.463	1.24 [0.69–2.23]
	GSE12093	Distant metastasis free survival	HG-U133A	136	0.599	0.86 [0.50–1.49]
	GSE11121	Distant metastasis free survival	HG-U133A	200	0.910	0.97 [0.58–1.63]
	GSE1378	Relapse free survival	Arcturus 22k	60	0.829	0.96 [0.66–1.39]
	GSE1379	Relapse free survival	Arcturus 22k	60	0.080	1.80 [0.93–3.46]
	GSE9893	Overall survival	MLRG Human 21K V12.0	155	0.001	0.72 [0.59–0.88]
	GSE2034	Distant metastasis free survival	HG-U133A	286	0.768	1.05 [0.77–1.43]
	GSE1456-GPL96	Relapse free survival	HG-U133A	159	0.326	0.77 [0.45–1.30]
	GSE1456-GPL96	Disease specific survival	HG-U133A	159	0.219	0.68 [0.37–1.26]
	GSE1456-GPL96	Overall survival	HG-U133A	159	0.107	0.65 [0.39–1.10]
	GSE7378	Disease free survival	U133AAofAv2	54	0.366	0.71 [0.34–1.50]
	E-TABM-158	Relapse free survival	HG-U133A	117	0.597	0.91 [0.65–1.28]
	E-TABM-158	Disease specific survival	HG-U133A	117	0.702	0.93 [0.63–1.37]
	E-TABM-158	Distant metastasis free survival	HG-U133A	117	0.448	0.85 [0.57–1.28]
	E-TABM-158	Overall survival	HG-U133A	117	0.597	0.91 [0.65–1.28]
	GSE3494-GPL96	Disease specific survival	HG-U133A	236		0.35 [0.20–0.62]
	GSE4922-GPL96	Disease free survival	HG-U133A	249	0.013	0.57 [0.36–0.89]
	GSE2990	Relapse free survival	HG-U133A	62	0.198	0.72 [0.44–1.18]
	GSE2990	Distant metastasis free survival	HG-U133A	125	0.037	0.53 [0.30–0.96]
	GSE2990	Relapse free survival	HG-U133A	125	0.004	0.52 [0.33–0.81]
	GSE2990	Distant metastasis free survival	HG-U133A	54	0.339	0.75 [0.41–1.36]
	GSE7390	Distant metastasis free survival	HG-U133A	198	0.749	1.04 [0.80–1.36]
	GSE7390	Overall survival	HG-U133A	198	0.886	0.98 [0.74–1.29]
	GSE7390	Relapse free survival	HG-U133A	198	0.781	1.03 [0.83–1.28]
Colorectal cancer	GSE12945	Disease free survival	HG-U133A	51	0.189	2.91 [0.59–14.36]
	GSE12945	Overall survival	HG-U133A	62	0.914	0.95 [0.39–2.32]
	GSE17536	Disease specific survival	HG-U133_Plus_2	177	0.739	1.07 [0.71–1.61]
	GSE17536	Overall survival	HG-U133_Plus_2	177	0.277	1.22 [0.85–1.73]
	GSE17536	Disease free survival	HG-U133_Plus_2	145	0.775	1.07 [0.66–1.74]
	GSE14333	Disease free survival	HG-U133_Plus_2	226	0.679	1.07 [0.77–1.50]
	GSE17537	Overall survival	HG-U133_Plus_2	55	0.821	1.07 [0.58–2.00]
	GSE17537	Disease free survival	HG-U133_Plus_2	55	0.532	1.24 [0.64–2.40]
	GSE17537	Disease specific survival	HG-U133_Plus_2	49	0.304	1.54 [0.68–3.51]
Lung cancer	jacob-00182-CANDF	Overall survival	HG-U133A	82	0.503	0.79 [0.40–1.56]
	HARVARD-LC	Overall survival	HG-U95A	84	0.551	1.15 [0.73–1.81]
	jacob-00182-HLM	Overall survival	HG-U133A	79	0.784	0.94 [0.58–1.50]
	MICHIGAN-LC	Overall survival	HuGeneFL	86	0.141	0.51 [0.21–1.25]
	jacob-00182-MSK	Overall survival	HG-U133A	104	0.013	0.48 [0.26–0.85]
	GSE13213	Overall survival	G4112F	117	0.025	0.70 [0.51–0.96]
	GSE31210	Overall survival	HG-U133_Plus_2	204	0.259	0.69 [0.37–1.31]
	GSE31210	Relapse free survival	HG-U133_Plus_2	204		0.42 [0.27–0.66]
	jacob-00182-UM	Overall survival	HG-U133A	178	0.189	0.75 [0.49–1.15]
	GSE3141	Overall survival	HG-U133_Plus_2	111	0.775	1.07 [0.68–1.68]
	GSE14814	Overall survival	HG-U133A	90	0.080	0.55 [0.29–1.07]
	GSE14814	Disease specific survival	HG-U133A	90	0.029	0.43 [0.20–0.92]
	GSE8894	Relapse free survival	HG-U133_Plus_2	138	0.857	1.02 [0.83–1.25]
	GSE4573	Overall survival	HG-U133A	129	0.575	1.22 [0.62–2.40]
	GSE17710	Relapse free survival	Agilent-UNC-custom-4X44K	56	0.545	0.85 [0.50–1.44]
	GSE17710	Relapse free survival	Agilent-UNC-custom-4X44K	56	0.332	0.79 [0.49–1.27]
	GSE17710	Overall survival	Agilent-UNC-custom-4X44K	56	0.283	0.74 [0.43–1.28]
	GSE17710	Overall survival	Agilent-UNC-custom-4X44K	56	0.133	0.68 [0.41–1.12]
Ovarian cancer	GSE9891	Overall survival	HG-U133_Plus_2	278	0.485	0.94 [0.80–1.11]
	DUKE-OC	Overall survival	HG-U133A	133	0.199	0.91 [0.79–1.05]
	GSE8841	Overall survival	G4100A	81	0.203	1.82 [0.72–4.56]
	GSE26712	Overall survival	HG-U133_Plus_2	185	0.269	1.16 [0.89–1.50]
	GSE26712	Disease free survival	HG-U133_Plus_2	185	0.248	1.15 [0.91–1.46]
	GSE17260	Progression free survival	G4112A	110	0.237	0.89 [0.73–1.08]
	GSE17260	Overall survival	G4112A	110	0.342	0.88 [0.69–1.14]
	GSE14764	Overall survival	HG-U133A	80	0.706	1.07 [0.75–1.53]
Prostate cancer	GSE16560	Overall survival	6K DASL	281		0.66 [0.54–0.81]
Renal cell carcinoma	E-DKFZ-1	Overall survival	A-RZPD-20	59	0.525	1.68 [0.34–8.29]
Skin cancer	GSE19234	Overall survival	HG-U133_Plus_2	38	0.021	0.50 [0.28–0.90]
Soft tissue cancer	GSE30929	Distant recurrence free survival	HG-U133A	140	0.348	1.28 [0.76–2.16]
Esophagus cancer	GSE11595	Overall survival	CRUKDMF_22K_v1.0.0	34	0.408	2.56 [0.28–23.76]
Eye cancer	GSE22138	Distant metastasis free survival	HG-U133_Plus_2	63		0.67 [0.54–0.84]
Head and neck cancer	GSE2837	Relapse free survival	U133_X3P	28	0.18	0.81 [0.59–1.10]
HR – hazard ratio; CI – confidence interval.

Back to the Article

Special AT-rich Sequence Binding-Protein 1 (SATB1) Correlates with Immune Infiltration in Breast, Head and Neck, and Prostate Cancer

Your Privacy